Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
33%(2 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_1
5
71%
Ph phase_3
2
29%

Phase Distribution

5

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
5(71.4%)
Phase 3Large-scale testing
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(6)
Terminated(1)

Detailed Status

Completed6
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (71.4%)
Phase 32 (28.6%)

Trials by Status

completed686%
terminated114%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_3

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

NCT02187003
terminatedphase_3

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

NCT02433158
completedphase_1

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

NCT02871570
completedphase_1

A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.

NCT02998099
completedphase_1

A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects

NCT02813798
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT02187003Phase 3

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

Completed
NCT02433158Phase 3

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

Terminated
NCT02871570Phase 1

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Completed
NCT02998099Phase 1

A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.

Completed
NCT02813798Phase 1

A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects

Completed
NCT02217917Phase 1

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects

Completed
NCT01941511Phase 1

A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7